Detailed price information for Catalyst Pharm Inc (CPRX-Q) from The Globe and Mail including charting and trades.

A notable Harris Poll survey conducted in 2022 found that as many as six in 10 Americans want to become a billionaire -- and ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

A new market analysis projects the global myelodysplastic syndrome (MDS) treatment market will grow from an estimated value ...

Cosmo Pharmaceuticals on Friday reported the renewal of its multi-year manufacturing and supply agreement with Takeda (TAK), ...

NDA for icotrokinra for the treatment of adults and adolescents 12 years of age and older with moderate to severe plaque ...

Takeda Pharmaceutical Company saw its drug Entyvio (vedolizumab) approved in China by the National Medical Products ...

Key Points GAAP loss per share of $0.55 in Q2 2025 beat analyst estimates by $1.13. GAAP revenue of $5.5 million in Q2 2025 missed expectations by 26%. Advanced key clinical programs, with first U.S.

Fintel reports that on August 6, 2025, Leerink Partners initiated coverage of Xilio Therapeutics (NasdaqGS:XLO) with a ...

Discover Novavax's Q2 2025 earnings insights: raised revenue targets, cost reductions, key partnerships with Sanofi & Takeda, and progress in ...